Literature DB >> 20237149

Thromboxane prostanoid receptor stimulation induces shedding of the transmembrane chemokine CX3CL1 yet enhances CX3CL1-dependent leukocyte adhesion.

Soumitra Tole1, Anne M Durkan, Yi-Wei Huang, Guang Ying Liu, Alexander Leung, Laura L Jones, Jasmine A Taylor, Lisa A Robinson.   

Abstract

In atherosclerosis, chemokines recruit circulating mononuclear leukocytes to the vascular wall. A key factor is CX(3)CL1, a chemokine with soluble and transmembrane species that acts as both a chemoattractant and an adhesion molecule. Thromboxane A(2) and its receptor, TP, are also critical to atherogenesis by promoting vascular inflammation and consequent leukocyte recruitment. We examined the effects of TP stimulation on processing and function of CX(3)CL1, using CX(3)CL1-expressing human ECV-304 cells and primary human vascular endothelial cells. TP agonists promoted rapid shedding of cell surface CX(3)CL1, which was inhibited by pharmacological inhibitors or specific small interfering RNA targeting tumor necrosis factor-alpha-converting enzyme (TACE). Because it reduced cell surface CX(3)CL1, we predicted that TP stimulation would inhibit adhesion of leukocytes expressing the CX(3)CL1 cognate receptor but, paradoxically, saw enhanced adhesion. We questioned whether the enhanced ability of the remaining membrane-associated CX(3)CL1 to bind targets was caused by changes in its lateral mobility. Using fluorescence recovery after photobleaching, we found that plasmalemmal CX(3)CL1 was initially tethered but ultimately mobilized by TP agonists. TP stimulation provoked clustering of transmembrane CX(3)CL1 at sites of contact with adherent leukocytes. These data demonstrate that TP stimulation induces two distinct effects: a rapid cleavage of surface CX(3)CL1, thereby releasing the soluble chemoattractant, plus mobilization of the remaining transmembrane CX(3)CL1 to enhance the avidity of interactions with adherent leukocytes. The dual effect of TP allows CX(3)CL1 to recruit leukocytes to sites of vascular inflammation while enhancing their adhesion once recruited.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237149     DOI: 10.1152/ajpcell.00380.2009

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  6 in total

1.  Altered post-capillary and collecting venular reactivity in skeletal muscle with metabolic syndrome.

Authors:  Kent A Lemaster; Zahra Farid; Robert W Brock; Carl D Shrader; Daniel Goldman; Dwayne N Jackson; Jefferson C Frisbee
Journal:  J Physiol       Date:  2017-07-05       Impact factor: 5.182

2.  Mitogen-activated protein kinase/IκB kinase/NF-κB-dependent and AP-1-independent CX3CL1 expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A.

Authors:  Su Hyuk Ko; Jong Ik Jeon; Hyunah Kim; Young-Jeon Kim; Jeehee Youn; Jung Mogg Kim
Journal:  J Mol Med (Berl)       Date:  2013-12-22       Impact factor: 4.599

Review 3.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

4.  Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.

Authors:  Peng Jiang; Stéphane Loyau; Maria Tchitchinadze; Jacques Ropers; Guillaume Jondeau; Martine Jandrot-Perrus
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

5.  Cytoskeletal confinement of CX3CL1 limits its susceptibility to proteolytic cleavage by ADAM10.

Authors:  Harikesh S Wong; Valentin Jaumouillé; Bryan Heit; Sasha A Doodnauth; Sajedabanu Patel; Yi-Wei Huang; Sergio Grinstein; Lisa A Robinson
Journal:  Mol Biol Cell       Date:  2014-09-24       Impact factor: 4.138

6.  CX3CL1 (fractalkine) protein expression in normal and degenerating mouse retina: in vivo studies.

Authors:  Marina Zieger; Peter K Ahnelt; Pavel Uhrin
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.